Home Regulatory Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

by admin
0 comment
Pfizerbiontech, First, FDA, Authorized, Covid19, Vaccine, Emergency, Use, In, Children, Under12, American, German, Multinational, Pharmaceutical, Biotechnology, Good, News, Approval, Euagency, Coronavirus, Vaccine, First, Opportunity, Children, Fda, WHO, Stringent, Authority, Paediatrics.

Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), and UBE Corporation (UBE) today announced that the U.S. Food and Drug Administration (FDA) has approved OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. The approval date was September 22.


Omidenepag isopropyl Structure

Omidenepag isopropyl Structure

  • API– Omidenepag isopropyl
  • DescriptionOMLONTI® is developed jointly by Santen and UBE. Omidenepag isopropyl, the active pharmaceutical ingredient in OMLONTI®, developed by UBE, is a relatively selective prostaglandin EP2 receptor agonist, which increases aqueous humor drainage through the conventional (or trabecular) and uveoscleral outflow pathways, and the only product with this pharmacological action. OMLONTI® was launched in Japan as Eybelis® ophthalmic solution 0.002% in November 2018, and was filed for marketing approval in Asian countries in stages. The product was released in five countries and regions beginning in February 2021.
  • Type -Small Molecule
  • Associated Conditions -Glaucoma
  • CAS number -1187451-19-9
  • MOAOmidenepag isopropyl is an agonist of the prostaglandin EP2 receptor indicated in the treatment of glaucoma.
  • IndicationOMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


The safety of OMLONTI® has been evaluated in 12 clinical studies, 10 of which investigated the safety of OMLONTI® in QD dosing. The results from these clinical trials indicate that OMLONTI® is safe and well tolerated by adult subjects (N=1111) with a diagnosis of open-angle glaucoma or ocular hypertension, and by pediatric subjects (N=6) with juvenile open-angle glaucoma. The risks identified with instillation of OMLONTI® include macular edema, including CME, in patients with aphakia, pseudophakia, or other risk factors for macular edema; ocular inflammation; the possibility of increased eye pigmentation; and eyelash changes.

“Glaucoma prevalence is increasing as the global population ages. Supporting patients by protecting vision across the continuum of clinical care in glaucoma is a significant aim for Santen to reduce the social and economic opportunity loss of people around the world caused by eye conditions,” explains Peter Sallstig, Chief Medical Officer of Santen. “This approval is an important milestone in our ambition to tackle unmet needs in eye health and advances our goal of realization of “Happiness with Vision”. It also represents our first glaucoma offering in the U.S. We are pleased to provide doctors and patients in the U.S. with a new option to help control IOP for the more than three million Americans affected by glaucoma or ocular hypertension.”

“UBE Corporation is committed to working on new drug discoveries on a daily basis with the aim of providing patients with more treatment options for diseases with high unmet needs,” said Yoichi Funayama, Senior Executive Officer and General Manager of the Pharmaceutical Division, UBE Corporation. “We are very pleased that this ophthalmic solution has been approved for glaucoma in the U.S., following approvals in Japan and Asia. We have high expectations that omidenepag isopropyl will provide a new treatment option for more patients suffering from glaucoma and ocular hypertension through Santen.”

OMLONTI® was evaluated in three randomized and controlled clinical trials in subjects with open-angle glaucoma or ocular hypertension with average baseline IOP of 24-26 mm Hg. The double-masked treatment duration was three months in all three studies. The third study included a 9-month open-label treatment period following the 3-month double-masked treatment period. In the three studies, IOP reductions were observed for all treatment arms. In the OMLONTI® arm, the reduction in IOP ranged from 5-7 mm Hg across all three studies. The corresponding reductions for the timolol and latanoprost arms were 5-7 mm Hg and 6-8 mm Hg, respectively.

About Santen

As a global specialized company dedicated to eye health, Santen brings a more than 130-year history of scientific knowledge and organizational capabilities to research, development, and commercialization of pharmaceutical, surgical, and OTC eye care products. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan, and its products now reach patients in more than 60 countries. Santen provides products and services to contribute to the well-being of patients, their loved ones, and consequently to society.

About UBE Corporation

Leveraging the manufacturing technologies the UBE groups has cultivated, UBE creates the value required by society, in the safe and environmentally friendly manner demanded by society, and delivers that value to the people. UBE helps to solve global environmental issues, which have become a common issue for all humankind, and contribute to people’s lives and health, and an enriched future society. UBE aims to contribute to better health for everyone with community-based manufacturing of drugs using innovative technologies. Going forward, UBE will continue creating promising new compounds for new medicines with a dual approach of pursuing drug discovery through internal and joint research and development projects, and manufacturing and supply of APIs and intermediates.

Weblink: https://www.chemrobotics.com

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Our Company

ChemRobotics is a global Scientific, Technical & Business data intelligence company, especially in the field of Pharmaceutical, Agrochemical, Veterinary and Fine Chemical.

ChemRobotics Times

Subscribe ChemRobotics for the latest updates in the Pharmaceutical, Agrochemical, Veterinary, and Fine Chemical Industries

Laest News

ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved. 

Designed and Developed by Ample eBusiness